Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10 | $95 | $99 | $105 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $1 | $13 | $14 | $17 |
| Enterprise Value | $12 | $107 | $112 | $121 |
| Revenue | $1 | $6 | $6 | $7 |
| % Growth | -86.7% | -4.5% | -13.1% | – |
| Gross Profit | -$0 | $5 | $5 | $6 |
| % Margin | -16.3% | 76.9% | 75.4% | 78.5% |
| EBITDA | $0 | $2 | $2 | $3 |
| % Margin | 47% | 30.8% | 35.5% | 34.9% |
| Net Income | -$0 | $1 | $1 | $1 |
| % Margin | -37.2% | 10.3% | 13.5% | 18.8% |
| EPS Diluted | -0.89 | 1.83 | 2.52 | 4.03 |
| % Growth | -148.6% | -27.4% | -37.5% | – |
| Operating Cash Flow | $0 | $1 | $2 | $2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $1 | $2 | $2 |